16:17 , May 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest the PPARγ agonist Avandia rosiglitazone could help treat melanoma. In a mouse model of melanoma, Avandia plus an irradiated GM-CSF-secreting tumor cell vaccine and an anti-CTLA-4 mAb decreased tumor incidence and...
18:30 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

BriaCell's Bria-IMT leads to tumor regressions in Phase I/IIa for breast cancer

BriaCell Therapeutics Corp. (TSX-V:BCT; OTCQB:BCTXF) reported data from six patients with stage IV breast cancer in the Phase I/IIa WRI-GEV-007 trial showing that Bria-IMT (SV-BR-1-GM) led to tumor regression in two patients, including one with...
20:15 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

BriaVax: Ph I/IIa start

This quarter, BriaCell will begin an open-label, U.S. Phase I/IIa trial to evaluate intradermal BriaVax comprising 20×106 cells given every 2 weeks for the first month and then monthly for up to 1 year in...